Highest development stage: Phase 2

Development active

Gram-positive activity

Mechanism of Action/Target pathogen: Developed for the treatment of COPD and influenza-exacerbated, neutrophil-mediated respiratory tract dysfunction

Additional information: Johnson. M., Wilfret. D., Chen. S., Jones. L., Bloomer. J., Peat. A."First Time Single and Repeated Dose IV Administration and Absolute Bioavailability of a Novel CXCR2 Antagonist, GSK1325756 (Danirixin); Study NCT02169583 " Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 2015.